Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug186 | Acacia Senegal Wiki | 0.58 |
| drug4075 | Transpulmonary thermodilution Wiki | 0.58 |
| drug2843 | Pectin Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018754 | Ventricular Dysfunction NIH | 0.67 |
| D018487 | Ventricular Dysfunction, Left NIH | 0.67 |
| D018497 | Ventricular Dysfunction, Right NIH | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0003003 | Colon cancer HPO | 0.29 |
| HP:0002092 | Pulmonary arterial hypertension HPO | 0.29 |
Navigate: Correlations HPO
There are 3 clinical trials
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a public health emergency of international concern. Hospitalized COVID-19-positive patients requiring ICU care is increasing along with the course of epidemic. A large number of these patients developed acute respiratory distress syndrome (ARDS) according to current data. However, the related hemodynamic characteristic has so far been rarely described.
Description: Body temperature(°C)
Measure: Body temperature Time: Through study completion, an estimation of 6 monthsDescription: Blood pressure in mmHg
Measure: Blood pressure Time: Through study completion, an estimation of 6 monthsDescription: Pulse (heart rate) in times/minute
Measure: Pulse (heart rate) Time: Through study completion, an estimation of 6 monthsDescription: Respiratory rate in times/minute
Measure: Respiratory rate Time: Through study completion, an estimation of 6 monthsDescription: Cardiac index (L/min/m2)
Measure: Data provided by transpulmonary thermodilution-CI Time: Through study completion, an estimation of 6 monthsDescription: Global end-diastolic volume(mL/m2)
Measure: Data provided by transpulmonary thermodilution-GEDV Time: Through study completion, an estimation of 6 monthsDescription: Extravascular lung water (mL/kg)
Measure: Data provided by transpulmonary thermodilution-EVLW Time: Through study completion, an estimation of 6 monthsDescription: Pulmonary vascular permeability index
Measure: Data provided by transpulmonary thermodilution-PVPI Time: Through study completion, an estimation of 6 monthsDescription: Left ventricle ejection fraction, Segmental left ventricle contractility, Speckle tracking data of the left and right ventricles, Dimensions of right and left cavities and Diastolic function of left ventricle
Measure: Incidence of new-onset or reversible systolic left ventricular dysfunction Time: Through study completion, an estimation of 6 monthsDescription: The worst extravascular lung water
Measure: Changes of extravascular lung water measured by transpulmonary thermodilution Time: Change from baseline extravascular lung water at 6 monthsDescription: The worst pulmonary vascular permeability index
Measure: Changes of pulmonary vascular permeability index measured by transpulmonary thermodilution Time: Change from baseline extravascular lung water at 6 monthsThe cardiovascular effects of coronavirus disease 2019 (COVID-19) are not yet fully known. We conducted a prospective and dynamic echocardiographic study to investigate the cardiac structural and functional changes in COVID-19 patients in intensive care unit (ICU).
Description: Death of any cause
Measure: Death Time: From admission to April 8 2020 (cutoff day)Cardiac dysfunction has been reported to be common in patients infected with COVID-19. The aim of this study is to evaluate the clinical importance of cardiac dysfunction in critically ill patients infected with COVID-19.
Description: All cause death in patients with vs without cardiac dysfunction
Measure: Mortality Time: 30 daysDescription: Prevalence of left ventricular dysfunction
Measure: Left ventricular dysfunction Time: Within 72 hours from admissionDescription: Prevalence of right ventricular dysfunction
Measure: Right ventricular dysfunction Time: Within 72 hours from admissionDescription: Clinical variables associated with risk of having cardiac dysfunction
Measure: Risk-factors Time: Within 72 hours from admissionDescription: Levels of cardiac biomarkers in patients with vs without cardiac dysfunction
Measure: Cardiac biomarkers Time: Within 72 hours from admissionDescription: Prevalence of left ventricular dysfunction
Measure: Left ventricular dysfunction Time: During ICU-stayDescription: Prevalence of right ventricular dysfunction
Measure: Right ventricular dysfunction Time: During ICU-stayDescription: Clinical variables associated with risk of having cardiac dysfunction
Measure: Risk-factors Time: During ICU-stayDescription: Levels of cardiac biomarkers in patients with vs without cardiac dysfunction
Measure: Cardiac biomarkers Time: During ICU-stayAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports